BioSpace News Archive

Progyny, Inc. announced its financial results for the three- and twelve-month periods ended December 31, 2022 as compared to the three- and twelve-month periods ended December 31, 2021.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been dosed in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.

Travere Therapeutics, Inc. announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $175,000,000 of its common stock.

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) and DMK Pharmaceuticals, Corp. today announced that the companies have entered into an Agreement and Plan of Merger and Reorganization (the “Agreement”).

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, February 28, 2023, at 8:30 a.m. Eastern Time to report its fourth quarter and full-year 2022 financial results and recent portfolio execution.

BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter and full year ended December 31, 2022.

ViewRay, Inc. announced financial results for the fourth quarter and full fiscal year ended December 31, 2022.

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 44th Annual Institutional Investors Conference on Monday, March 6, 2023, at 8:40 a.m. ET.

Theravance Biopharma, Inc. announced financial results for the fourth quarter and full year ended December 31, 2022.

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has submitted the fourth and final module of its modular submission to the FDA for premarket approval of Motiva Implants® in the United States.